Jacobio Pharmaceuticals

Jacobio Pharmaceuticals (加科思药业, 01167.HK) is a Hong Kong-listed oncology biotech in Qiming Venture Partners' portfolio, led by chairman and CEO Wang Yinxiang, with a pipeline built around KRAS and other hard-to-drug targets . Its trajectory over 2025-2026 reads as a shift from R&D stage to commercialization: in May 2025 its self-developed KRAS G12C inhibitor glecirasib (艾瑞凯) won NMPA approval for previously treated KRAS G12C-mutant non-small cell lung cancer — a milestone Wang described as the payoff of "a decade of attacking undruggable targets," and one that triggered a RMB 50 million milestone payment from partner Allist Pharmaceuticals . Beyond that, its SHP2 inhibitor sitneprotafib (JAB-3312) has published combination-therapy data with PD-1 antibodies and RTK/RAS/MAPK-pathway drugs in Clinical Cancer Research . The biggest recent event: in December 2025 Jacobio licensed its oral pan-KRAS inhibitor JAB-23E73 to AstraZeneca, and by March 2026 had received the $100 million upfront payment under that deal .